EUVIMEDEUVIMED entdecken
Leitlinie

ADVANCES IN LEPROSY TREATMENT AND CLINICAL MANAGEMENT GUIDELINES

Isabella Zanatta Ribeiro, Wanny Tapajós Jácome, Ingrid da Silva Barreto, Alexandra Borja Mancheno, Erika Marques Bezerra, Danielle da Silveira, Selva Meirelles, Luceime Olivia Nunes, Brigida Maria Goncalves de Melo Brandao, Eduarda Polonio de Oliveira, Antonio da Silva Ribeiro, Lucas de Jesus Farias und 2 weitere

ARACÊ · 12.08.2026 · 8 (8) · e14031

DOI: 10.56238/arev8n8-047 ↗

Kurz gefasst

Leitlinie in der Zeitschrift ARACÊ, online erschienen am 12.08.2026. Verfasst von Isabella Zanatta Ribeiro und 13 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Leprosy, a chronic infection caused by Mycobacterium leprae and the recently identified M. lepromatosis (Ebenezer; Scollard, 2021; Mehta et al., 2025), remains one of the major infectious causes of peripheral neuropathy and physical disability worldwide (Ebenezer; Scollard, 2021). This work analyzes recent advances in clinical management guidelines, therapeutic and diagnostic strategies for disease control. The fundamental pillar of treatment is based on polychemotherapy (PCT) standardized by the World Health Organization (WHO), combining rifampicin, dapsone, and clofazimine, according to the classification of paucibacillary (PB) and multibacillary (MB) (Chen et al., 2022). In scenarios of bacterial resistance or drug intolerance, alternative regimens with fluoroquinolones, macrolides, and minocycline have demonstrated relevant efficacy (Mehta et al., 2025). Noteworthy are the implementation of post-exposure chemoprophylaxis with single-dose rifampicin (SDR-PEP) and the development of T-cell subunit vaccines (Huang et al., 2024). Control of disabilities is based on early management of lepra reactions and neuritis, using corticosteroids, thalidomide, and immunomodulators (Mehta et al., 2025). Advanced methods, such as high-resolution ultrasound with Doppler and nerve fiber biopsy, have revolutionized the detection of subclinical neural involvement (Ebenezer; Scollard, 2021; Huang et al., 2024). It is concluded that the consolidation of new pharmacological and prophylactic options is essential to reduce disease burden and prevent irreversible sequelae (Chen et al., 2022; Huang et al., 2024).

Zitieren

APA

Ribeiro, I. Z., Jácome, W. T., Barreto, I. D. S., Mancheno, A. B., Bezerra, E. M., Silveira, D. D., Meirelles, S., Nunes, L. O., Brandao, B. M. G. D. M., Oliveira, E. P. D., Ribeiro, A. D. S., Farias, L. D. J., Dantas, A. L. N., & Lima, P. H. D. (2026). ADVANCES IN LEPROSY TREATMENT AND CLINICAL MANAGEMENT GUIDELINES. ARACÊ, 8(8), e14031. https://doi.org/10.56238/arev8n8-047

Vancouver

Ribeiro IZ, Jácome WT, Barreto IDS, Mancheno AB, Bezerra EM, Silveira DD, et al. ADVANCES IN LEPROSY TREATMENT AND CLINICAL MANAGEMENT GUIDELINES. ARACÊ. 2026;8(8):e14031. doi:10.56238/arev8n8-047

BibTeX
@article{Ribeiro2026,
  author = {Ribeiro, Isabella Zanatta and Jácome, Wanny Tapajós and Barreto, Ingrid da Silva and Mancheno, Alexandra Borja and Bezerra, Erika Marques and Silveira, Danielle da and Meirelles, Selva and Nunes, Luceime Olivia and Brandao, Brigida Maria Goncalves de Melo and Oliveira, Eduarda Polonio de and Ribeiro, Antonio da Silva and Farias, Lucas de Jesus and Dantas, André Lucas Nogueira and Lima, Paulo Henrique Dias},
  title = {ADVANCES IN LEPROSY TREATMENT AND CLINICAL MANAGEMENT GUIDELINES},
  journal = {ARACÊ},
  year = {2026},
  volume = {8},
  number = {8},
  pages = {e14031},
  doi = {10.56238/arev8n8-047}
}
Kostenlos starten →